Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971995 | 0.88 | USP2 (0.37) | MEN1ALDH1A1MAPTKMT2ACTSK | |
| SCHEMBL3589272 | 0.81 | CYP4F2 (0.34) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL5276929 | 0.80 | CYP2C19 (0.40) | HRH3DPP4 | |
| SCHEMBL3295941 | 0.78 | MEN1 (0.36) | MEN1ALDH1A1MAPTKMT2ACTSK | |
| SCHEMBL3296876 | 0.76 | CTSK (0.35) | MEN1ALDH1A1MAPTKMT2ACTSK | |
| SCHEMBL3592215 | 0.76 | CYP4F2 (0.36) | CTSKCYP4F2CYP4A11 | |
| SCHEMBL3295202 | 0.74 | CYP4F2 (0.39) | CYP4F2CYP4A11 | |
| SCHEMBL18182125 | 0.72 | CYP4F2 (0.37) | CTSKCYP4F2CYP4A11 | |
| SCHEMBL2989855 | 0.71 | DRD2 (0.43) | KMT2AEPHX1 | |
| SCHEMBL3293795 | 0.70 | DRD2 (0.46) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737163-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7705020-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7595329-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080108660-A1 | Benzimidazolone Carboxylic Acid Derivatives | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277671-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277673-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277673-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | MEN1 524/4885ALDH1A1 1109/4885MAPT 1910/4885 |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | MEN1 524/4885ALDH1A1 1109/4885MAPT 1910/4885 |
| US-20050277671-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | MEN1 524/4885ALDH1A1 1109/4885MAPT 1910/4885 |
| US-20080108660-A1 | Benzimidazolone Carboxylic Acid Derivatives | HRH2, HRH4, GPR4 | MEN1 452/4885ALDH1A1 1018/4885MAPT 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.